Study on Using Risk Factors to Decide Treatment for Children with Favorable Histology Wilms Tumors

Program Overview

This clinical trial is investigating how different risk factors can guide treatment decisions for children with Favorable Histology Wilms Tumor (FHWT), a common kidney cancer in children. By examining tumor characteristics and how they respond to initial treatments, researchers aim to tailor therapies to improve outcomes and reduce the risk of cancer relapse. The study will use information from tumor tests and patient responses to adjust treatment plans, potentially leading to better survival rates for children with FHWT.

Description

The main goal of this study is to find the best treatment approach for children with Favorable Histology Wilms Tumor (FHWT) by considering various risk factors. These factors include the child's age, tumor size, and specific biological features of the tumor. The study will test different combinations of chemotherapy drugs and surgery to see which works best for different groups of patients.

For children with Stage I FHWT, the study will explore whether some can safely receive less treatment after surgery, while others may need additional chemotherapy. For Stage II and III patients, the study will compare different chemotherapy regimens to find the most effective one. Stage IV patients will be evaluated to see if adding more intensive treatments can improve outcomes.

The study will also look at how imaging tests, like CT scans and MRIs, can help detect cancer spread and guide treatment decisions. Researchers will collect blood and urine samples for future research and monitor patients for up to 10 years after treatment to track long-term outcomes.

Overall, the study aims to personalize treatment for children with FHWT, improving their chances of recovery and reducing the risk of cancer returning.

Eligibility Criteria

Locations